Local neurotoxicity and myotoxicity evaluation of cyclodextrin complexes of bupivacaine and ropivacaine

Anesthesia and Analgesia

Volumn 115, Issue 5, 2012, Pages 1234-1241

  Cereda, Cintia Maria Saia ^a   Tofoli, Giovana Radomille ^b   Maturana, Luiz Gabriel ^c   Pierucci, Amauri ^c   Nunes, Lazaro Alessandro Soares ^a   Franz Montan, Michelle ^a   De Oliveira, Alexandre Leite Rodrigues ^d   Arana, Sarah ^a   De Araujo, Daniele Ribeiro ^e   De Paula, Eneida ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSIDADE SÃO FRANCISCO   (Brazil)

^c UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI   (Brazil)

^d Biology Institute   (Brazil)

^e UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BUPIVACAINE HYDROXYPROPYL BETA CYCLODEXTRIN; LOCAL ANESTHETIC AGENT; ROPIVACAINE HYDROXYPROPYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOTOXICITY; DRUG FORMULATION; ENZYME ACTIVITY; GASTROCNEMIUS MUSCLE; HISTOPATHOLOGY; MALE; MUSCLE DISEASE; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SCHWANN CELL; SCIATIC NERVE;

AMIDES; ANIMALS; ANIMALS, NEWBORN; BUPIVACAINE; CELLS, CULTURED; CYCLODEXTRINS; DRUG EVALUATION, PRECLINICAL; MALE; MUSCULAR DISEASES; RATS; RATS, WISTAR; SCIATIC NERVE;

EID: 84868214401     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318266f3d9     Document Type: Article

References (53)

1. Cederholm I. Preliminary risc-benefit analisys of ropivacaine in labour and following surgery. Drug Saf 1997;16:391-402
2. Koehler A, Oertel R, Kirch W. Simultaneous determination of bupivacaine, mepivacaine, prilocaine and ropivacaine in human serum by liquid chromatography-tandem mass spectrometry. J Chrom 2005;1088:126-30
3. Mather L, Chang DHT. Cardiotoxicity with modern local anesthetics: is there a safer choice? Drugs 2001;61:333-42
4. Mcclellan K, Faulds D. Ropivacaine: an update of its use in regional anesthesia. Drugs 2001;60:1065-93
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discovery 2005;4:145-60
6. de Paula E, Cereda CMS, Tofoli GR, Franz-Montan M, Fraceto LF, Araujo DR. Drug delivery systems for local anesthetics. Rec Pat Drug Deliv Formulat 2010;4:23-34
7. Dollo G, Thompson D, Le Corre P, Chevanne F, Le Verge R. Inclusion complexation of amide-type local anesthetics with β-cyclodextrin and derivates: .III. Biopharmaceutics of bupivacaine-HP β-CD complex following percutaneous sciatic nerve administration in rabbits. Int J Pharm 1998;164:11-9
8. Dollo G, Le Corre P, Freville JC, Chevanne F, Le Verge R. Biopharmaceutics of local anesthetic cyclodextrin complexes following loco-regional administration. Ann Pharm Fr 2000;58:425-32
9. Araujo DR, Braga AFA, Fraceto LF, de Paula E. Drug-delivery systems for racemic bupivacaine (S50-R50) and bupivacaine enantiomeric mixture (S75-R25): cyclodextrins complexation effects on sciatic nerve blockade in mice. Rev Bras Anesthesiol 2005;55:316-27
10. Araujo DR, Braga AFA, Moraes CM, Fraceto LF, de Paula E. Complexation of 50% enantiomeric excess (S75-R25) bupivacaine with cyclodextrins and spinal block anesthesia in rats. Rev Bras Anesthesiol 2006;56:495-06
11. Araujo DR, Tsuneda SS, Cereda CMS, Carvalho FGF, Preté PSC, Fernandes SA, Yokaichiya F, Franco MK, Mazzaro I, Fraceto LF, Braga AFA, de Paula E. Development and pharmacological evaluation of ropivacaine-2- hydroxypropyl-beta-cyclodextrin inclusion complex. Eur J Pharm Sci 2008;33:60-71
12. Hammarberg H, Risling M, Hökfelt T, Cullheim S, Piehl F. Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries. J Comp Neurol 1998;400:57-72
13. Pierucci A, Faria AM, Pimentel ER, Santos Jr AR, Oliveira ALR. Effects of aggrecan on Schwann cell migration in vitro and nerve regeneration in vivo. Braz. J. Morphol. Sci 2004;21:125-30
14. Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya N, Kinoshita M. Deprenyl and pergolide rescue spinal motor neurons from axotomy-induced neuronal death in the neonatal rat. Neurol Res 1996;18:168-70
15. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;22:271-7
16. Welder AA. A primary culture system of adult rat heart cells for the evaluation of cocaine toxicity. Toxicology 1992;72:175-87
17. Andreescu S, Sadik OA, McGee DW. Effect of natural and synthetic estrogens on a549 lung cancer cells: correlation of chemical structures with cytotoxic effects. Chem Res Toxicol 2005;18:466-74
18. Iohom G, Lan GB, Diarra DP, Grignon Y, Kinirons BP, Girard F, Merle M, Granier G, Cahn V, Bouaziz H. Long-term evaluation of motor function following intraneural injection of ropivacaine using walking track analysis in rats. Br J Anaesth 2005;94:524-9
19. Myers RR, Sommer C. Methodology for spinal neurotoxicity studies. Reg. Anesth 1993;18:439-47
20. Dyhre H, Söderberg L, Björkman S, Carlsson C. Local anesthetics in lipid-depot formulations-neurotoxicity in relation to duration of effect in a rat model. Reg Anesth Pain Med 2006;31:401-8
21. Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm 2001;212:11-8
22. Benoit WP, Yagiela JA, Ferrell Fort N. Pharmacologic correlation between local anesthetic-induced myotoxicity and disturbances of intracellular calcium distribution. Toxicol Appl Pharmacol 1980;52:187-98
23. Zink W, Seif C, Bohl JR, Hacke N, Braun PM, Sinner B, Martin E, Fink RH, Graf BM. The acute myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blockades. Anesth Analg 2003;97:1173-9
24. Zink W, Bohl JR, Hacke N, Sinner B, Martin E, Graf BM. The long term myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blocks. Anesth Analg 2005;101:548-54
25. Amaniti E, Drampa F, Kouzi-Loliakos K, Kapoukranidou D, Pouzitaki C, Vasilakos D. Ropivacaine myotoxicity after singel intramuscular injection in rats. Eur J Anaesthesiol 2006;23:130-5
26. Zar JH: Biostatistical Analysis. 5th ed. Upper Saddle River, NJ, Prentice Hall, 2010
27. Kalichman MW, Moorhouse DF, Powell HC, Myers RR. Relative neural toxicity of local anesthetics. J Neuropathol Exp Neurol 1993;52:234-40
28. Sakura S, Kirihara Y, Muguruma T, Kishimoto T, Saito Y. The comparative neurotoxicity of intrathecal lidocaine and bupivacaine in rats. Anesth Analg 2005;101:541-7
29. Lirk P, Haller I, Myers RR, Klimaschewski L, Kau YC, Hung YC, Gerner P. Mitigation of direct neurotoxic effects of lidocaine and amitriptyline by inhibition of p38 mitogen-activated protein kinase in vitro and in vivo. Anesthesiology 2006;104: 1266-73
30. Kuzma P J, Kline MD, Calkins MD, Staats PS. Progress in the development of ultra-long-acting local anesthetics. Reg Anesth 1997;22:543-51
31. Boogaerts JG, Lafont ND, Luo H, Legros FJ. Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbits. Can J Anaesth 1993;40:1201-4
32. Malinovsky JM, Benhamou D, Alafandy M, Mussini JM, Coussaert C, Couarraze G, Pinaud M, Legros FJ. Neurotoxicological assessment after intracisternal injection of liposomal bupivacaine in rabbits. Anesth Analg 1997;85:1331-6
33. Araujo DR, Cereda CMS, Brunetto GB, Vomero VU, Pierucci A, Santo Neto H, Oliveira ALR, Fraceto LF, Braga AFA, de Paula E. Pharmacological and local toxicity studies of a liposomal formulation for the novel local anaesthetic ropivacaine. J Pharm Pharmacol 2008;60:1449-57
34. Zhang H, Lu Y, Zhang G, Gao S, Sun D, Zhong Y. Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres: I. Optimization of the drug incorporation into the polymer matrix and modeling of drug release. Intl J Pharm 2008;351:244-49
35. Tanaka PP, Estèbe JP, Campos R, Chevanne F, Le Corre P, Tenório SB, Torres MF. Preparation, characterization and in vitro evaluation of 50% enantiomeric excess bupivacaine (S75-R25)-loaded microspheres. Rev Bras Anestesiol 2008; 58:15-22
36. Grillo R, de Melo NF, de Araujo DR, de Paula E, Rosa AH, Fraceto LF. Polymeric alginate nanoparticles containing the local anesthetic bupivacaine. J Drug Target 2010;18(9):688-99
37. Butterworth JF, Strichartz GR. Molecular mechanisms of local anesthesia: a review. Anesthesiology 1990;72: 711-34
38. de Paula E, Schreier S, Jarrell HC, Fraceto LF. Preferential location of lidocaine and etidocaine in lecithin bilayers as determined by EPR, fluorescence and 2H NMR. Biophys Chem 2008;132:47-54
39. .Nava-Ocampo AA, Bello-Ramirez AM. Lipophilicity affects the pharmacokinetics and toxicity of local anesthetic agents administered by caudal block. Clin Exp Pharmacol Physiol 2004;31:116-8
40. Malheiros SV, Pinto LM, Gottardo L, Yokaichiya DK, Fraceto LF, Meirelles NC, de Paula E. A new look at the hemolytic effect of local anesthetics, considering their real membrane/ water partitioning at pH 7.4. Biophys Chem 2004;110: 213-21
41. Motoyama K, Arima H, Toyodome H, Irie T, Hirayama F, Uekama K. Effect of 2-6-di-O-methyl-alpha-cyclodextrin on hemolysis and morphological change in rabbit's red blood cells. Eur J Pharm Sci 2006;29:111-9
42. Werdehausen R, Fazeli S, Braun S, Hermanns H, Essmann F, Hollmann MW, Bauer I, Stevens MF. Apoptosis induction by different local anaesthetics in a neuroblastoma cell line. Br J Anaesth 2009;103:711-18
43. Zink W, Graf BM, Sinner B, Martin E, Fink RH, Kunst G. Differential effects of bupivacaine on intracellular Ca2+ regulation: potential mechanisms of its myotoxicity. Anesthesiology 2002;97:710-6
44. Irwin W, Fontaine E, Agnolucci L, Penzo D, Betto R, Bortolotto S, Reggiani C, Salviati G, Bernardi P. Bupivacaine myotoxicity is mediated by mitochondria. J Biolog Chem 2002;14: 12221-7
45. Padera RF, Tse JY, Bellas E, Kohane DS. Tetrodotoxin for prolonged local anesthesia with minimal myotoxicity. Muscle Nerve 2006;34:747-53
46. Padera R, Bellas E, Tse JY, Hao D, Kohane D. Local myotoxicity from sustained release of bupivacaine from microparticles. Anesthesiology 2008;108:921-8
47. Gould S, Scott RC. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 2005;43:1451-9
48. Bouaziz H, Iohom G, Estebe JP, Campana WM, Myers RR. Effects of levobupivacaine and ropivacaine on rat sciatic nerve blood flow. Br J Anaesth 2005;95:696-700
49. Rajewski RA, Traiger G, Bresnahan J, Jaberaboansari P, Stella VJ. Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J Pharm Sci 1995;84:927-32
50. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol 1976;83:367-82
51. Frijlink HW, Visser J, Hefting NR, Oosting R, Meijer DKF, Lerk CF. The pharmacokinetics of β-cyclodextrin in the rat. Pharm Res 1990;7:9-16
52. Frijlink HW, Eissens AC, Hefting NR, Poelstra K, Lerk CF, Meijer DKF. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm Res 1991;8:1248-52
53. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews. 2004;3:1023-35.